APOPHARMA USA

Serial Number 86958426
606

Registration Progress

Application Filed
Mar 30, 2016
Under Examination
Jun 6, 2017
Approved for Publication
Apr 11, 2017
Published for Opposition
Apr 11, 2017
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: APOPHARMA USA
Previous Owner: APOTEX INC.
Classes: 005

Trademark Image

APOPHARMA USA

Basic Information

Serial Number
86958426
Filing Date
March 30, 2016
Published for Opposition
April 11, 2017
Abandonment Date
July 13, 2020
Drawing Code
3

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Jul 13, 2020
Classes
005

Rights Holder

APOTEX INC.

03
Address
150 SIGNET DRIVE
TORONTO, ONTARIO M9L1T9
CA

Ownership History

Apotex Technologies Inc.

Original Applicant
03
Toronto, Ontario CA

Apotex Technologies Inc.

Owner at Publication
03
Toronto, Ontario CA

APOTEX INC.

New Owner After Publication #1
03
TORONTO, ONTARIO CA

Legal Representation

Attorney
Robert A. Rowan

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

41 events
Date Code Type Description Documents
Jul 13, 2020 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Jul 13, 2020 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Nov 5, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 4, 2019 EX5G S SOU EXTENSION 5 GRANTED Loading...
Oct 31, 2019 EXT5 S SOU EXTENSION 5 FILED Loading...
Nov 4, 2019 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Oct 31, 2019 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 19, 2019 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
May 9, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 7, 2019 EX4G S SOU EXTENSION 4 GRANTED Loading...
May 7, 2019 EXT4 S SOU EXTENSION 4 FILED Loading...
May 7, 2019 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Dec 7, 2018 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Dec 5, 2018 EX3G S SOU EXTENSION 3 GRANTED Loading...
Dec 5, 2018 EXT3 S SOU EXTENSION 3 FILED Loading...
Dec 5, 2018 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 7, 2018 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jun 5, 2018 EX2G S SOU EXTENSION 2 GRANTED Loading...
Jun 5, 2018 EXT2 S SOU EXTENSION 2 FILED Loading...
Jun 5, 2018 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Dec 7, 2017 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Dec 5, 2017 EX1G S SOU EXTENSION 1 GRANTED Loading...
Dec 5, 2017 EXT1 S SOU EXTENSION 1 FILED Loading...
Dec 5, 2017 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 6, 2017 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Apr 11, 2017 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Apr 11, 2017 PUBO A PUBLISHED FOR OPPOSITION Loading...
Mar 22, 2017 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Mar 3, 2017 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Feb 23, 2017 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Feb 8, 2017 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Feb 8, 2017 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jan 31, 2017 ALIE A ASSIGNED TO LIE Loading...
Jan 11, 2017 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jul 19, 2016 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jul 19, 2016 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jul 19, 2016 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jul 13, 2016 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 5, 2016 MDSM E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Apr 4, 2016 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Apr 2, 2016 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations, namely, prescription drugs for the treatment of multiple myeloma by slowing the growth of cancer cells, prescription drugs for the treatment of multiple myeloma by stopping the growth of cancer cells, prescription drugs for palliative treatment of patients with multiple myeloma, and prescription drugs for use as an iron chelator for the treatment of patients with transfusion iron overload due to thalassemia syndromes, prescription drugs for the treatment of iron-associated neurodegenerative conditions, namely, Parkinson's disease and neurodegeneration with brain iron accumulation, in particular, pantothenate kinase-associated neurodegeneration

Additional Information

Design Mark
The mark consists of the word "APOPHARMA" with "USA" underneath and a swoosh design at the end.
Color Claim
Color is not claimed as a feature of the mark.
Pseudo Mark
APO PHARMA USA

Classification

International Classes
005

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"USA"